ArticleChinese medical journal2026

Induction alectinib or crizotinib for stage III NSCLC harboring ALK fusion: A study with 4-year follow-up.

Chao Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.